PIK3CA and neoplasm: Based on these results we may conclude that patient #12, who contains an EGFR L858R mutation as well as a PIK3CA C420R mutation in the tumor DNA, may be less responsive to EGFR or PIK3CA inhibitors, but this has not yet been confirmed by clinical studies.